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Methylation of specific lysine residues in the C ter-
minus of p53 is thought to govern p53-dependent
transcription following genotoxic and oncogenic
stress. In particular, Set7/9 (KMT7)-mediated mono-
methylationof humanp53at lysine372 (p53K372me1)
was suggested to be essential for p53 activation in
human cell lines. This finding was confirmed in a
Set7/9 knockout mouse model (Kurash et al., 2008).
In an independent knockout mouse strain deficient
in Set7/9, we have investigated its involvement in
p53 regulation and find that cells from these mice
are normal in their ability to induce p53-dependent
transcription following genotoxic and oncogenic
insults. Most importantly, we detect no impairment
in canonical p53 functions in these mice, indicating
that Set7/9-mediated methylation of p53 does not
seem to represent a major regulatory event and
does not appreciably control p53 activity in vivo.
INTRODUCTION
The tumor suppressor p53 is situated at a central signaling node
mediating cellular responses to stress and is mutated in a
majority of human cancers (Vousden and Lu, 2002). In response
to cellular stress such as DNA damage or aberrant oncogene
expression, p53 becomes stabilized and recruits a multitude of
transcriptional coregulators to coordinate a complex gene ex-
pression network resulting in cell-cycle arrest or apoptosis
(Brooks and Gu, 2003).
Reminiscent of signaling events on histone tails, site-specific
methylation and acetylation within the regulatory C terminus of
p53 have been proposed to either cooperate or counteract
each other, thereby controlling opposing p53 activation states
(Huang and Berger, 2008). Specifically, monomethylation of
lysine 372 in human p53 (p53K372me1) by Set7/9 has been
suggested to be a prerequisite for efficient p53-dependent
gene induction, cell-cycle arrest, and apoptosis (Chuikov et al.,
2004). p53K372me1 was found to inhibit the repressive mono-
methylation of K370 by Smyd2 (Huang et al., 2006) and has
been proposed to facilitate acetylation of K373 and K382 (Ivanov
et al., 2007). Thus, Set7/9-dependent methylation of p53 is cur-
rently considered a central regulatory event in the modulationMoof its transactivation potential. Importantly, however, most of
the data in support of this hypothesis were obtained from studies
in human cancer cell lines with compromised p53 activity.
Therefore, the physiological significance of p53 methylation in
primary cells largely remains to be investigated.
Kurash et al. (2008) reported that mice lacking Set7/9 display
severe impairments in a number of canonical p53 activities. They
showed that in response to genotoxic stress, p53 becomes
methylated on K369 (p53K369), and that this methylation is
absent in Set7/9/ cells. It was also reported that p53 acetyla-
tion on multiple other lysines is abrogated and that the induction
of two p53 target genes, p21WAF1/CIP and Puma, in response to
cellular stress is greatly reduced in Set7/9/ mice. As a result,
expression of the oncogenes E1A and H-RasV12 was reported
to easily transform MEFs lacking Set7/9. Based on this data,
the authors concluded that Set7/9 is critically required for the
tumor-suppressive function of p53 in primary mouse cells.
Here, we present data that not only cast doubt on the role of
Set7/9 in regulating p53, but also question the overall impact
of p53 C-terminal methylation on p53 activity in nontransformed
cells.
RESULTS
Generation of a Conditional Set7/9–/– Strain
To disrupt Set7/9 expression in the mouse, we chose a condi-
tional targeting approach in which the majority of the gene,
including the entire C terminus encoding the catalytically SET
domain, was flanked with loxP sites (Figure S1). The knockout
allele was then generated by crossing through a ubiquitous Cre-
expressing transgenic strain. All mice used for this study were
backcrossed into C57BL/6J for five generations. Their genetic
background was therefore presumably comparable with that of
the mice used by Kurash et al. (2008). Viable Set7/9/ offspring
were obtained at normal Mendelian ratios from Set7/9+/ inter-
crosses and did not display any gross abnormalities. Western
analysis with antibodies raised against the full-length protein
or an N-terminal peptide confirmed that we completely elimi-
nated expression of the Set7/9 protein from the excised locus
(Figure 1A). Further, although Set7/9 is classified as an H3K4-
specific methyltransferase, we detected no change in global
H3K4 methylation levels in Set7/9/MEFs (Figure 1A).
Interestingly, wild-type (WT) and Set7/9/ breeder pairs
consistently yield comparable litter sizes (7.14 ± 1.96, n = 14
and 6.83 ± 2.71, n = 6), an observation that is at oddswith a report
























































Figure 1. Characterization of a Set7/9 Conditional Knockout Strain
(A) Confirmation of the complete absence of Set7/9 in knockout MEFs. Global H3K4 methylation levels are unaffected in Set7/9/ cells.
(B) The a-p53K372me1 antiserum does not bind activated p53 in Adriamycin-treated MEFs. A strong Set7/9-dependent cross-reacting band is observed at
23 kDa. The asterisk indicates an unspecific band used as a loading control. (See also corresponding Figures S1 and S2.)
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Set7/9 Is Not Required for p53 Activityreceptor a (ERa) activity (Subramanian et al., 2008). Since ERa
is required for postnatal sexual maturation (Lubahn et al.,
1993), its impaired activity in Set7/9/ mice should result in
noticeably compromised male and female fertility. However,
our data suggest that Set7/9 does not play a discernible role in
the execution of ERa-dependent gene expression during sexual
maturation.
The reported role of Set7/9 in regulating p53 by methylating
p53K369 prompted us to investigate this modification in WT
versus Set7/9/ MEFs. We attempted to detect p53K369me1
in Adriamycin-treated cells using an antiserum raised against
human p53K372me1 (Abcam cat. #16033) (Chuikov et al.,
2004). Despite a divergent amino acid sequence (Figure S2A),
this antiserum was also reported to react with mouse
p53K369me1 (Kurash et al., 2008). In our hands, however, this
antibody did not recognize murine p53 in lysates from Adria-
mycin-treated WT or Set7/9/ cells (Figure 1B). Importantly,
while showing strong reactivity toward a synthetic methylated
human peptide spanning the sequence flanking p53K372me1
(Abcam #16203) in dot blot analyses, this antiserum entirely
failed to recognize the corresponding mouse peptide including
p53K369 in its methylated or unmethylated form (Figure S2B).
At the same time, we consistently detected a cross-reacting
protein of 23 kDa in whole-cell lysates of WT and p53/ but
not Set7/9/ MEFs (Figure 1B). This indicates that whereas
the antihuman p53K372me1 antiserum is not suitable to deter-
mine the methylation status of mouse p53K369, as claimed by
Kurash et al. (2008), it likely recognizes a monomethylated lysine
on an as-yet-unidentified Set7/9 substrate. Indeed, reintroduc-
tion of Set7/9 in Set7/9/ MEFs by retroviral transduction led
to the reappearance of the 23 kDa band, and the use of the
same antiserum in immunoprecipitation experiments revealed
the presence of a second protein that was recognized in WT
but not in Set7/9/ cells, about 43 kDa in size (Figures S2C
and S2D). These data demonstrate that we have generated
a functional knockout for Set7/9, but do not allow a definitive674 Molecular Cell 43, 673–680, August 19, 2011 ª2011 Elsevier Inc.conclusion about whether p53K369 is indeed a substrate for
Set7/9 in vivo.
Set7/9 Is Dispensable for p53-Dependent Senescence,
Transcription, Cell-Cycle Arrest, and Apoptosis
Since p53 plays a key role in the response to culture-associated
stress, cells deficient in p53 function escape culture-induced
cell-cycle arrest and are easily immortalized. To investigate
whether cells lacking Set7/9 display a similar impairment in
culture-induced senescence, we investigated the growth
kinetics of cultured MEFs from WT, Set7/9/, and p53/
mice following the 3T3 protocol (Todaro and Green, 1963).
p53/ MEFs grew exponentially throughout the culture period,
as expected. In contrast, both Set7/9/ and WT MEFs under-
went a replicative crisis after passage 9 (Figure 2A), indicating
that Set7/9 is not required for culture-induced senescencemedi-
ated by p53.
Genotoxic stress initiates the N-terminal serine phosphoryla-
tion of p53, blocking the interaction with Mdm2 and leading to
the accumulation of the protein (Prives, 1998). Overexpression
and RNAi experiments suggest that p53, once activated,
depends on SET7/9 to induce expression of its target genes
p21 and MDM2 (Chuikov et al., 2004) in human cells. We thus
compared low-passage MEFs from WT and Set7/9/ litter-
mates, along with p53/ controls, in their ability to stabilize
p53 and induce p53-dependent transcription and cell-cycle
arrest. We exposed MEFs to gamma radiation, Adriamycin, or
the Mdm2 antagonist Nutlin 3 and compared protein levels of
p53, p21, Mdm2, and Puma 18 hr after these treatments (Fig-
ure 2B). Under all conditions tested, we detected no expression
of p21 and Mdm2 and only weak expression of Puma in p53/
cells, as expected. By contrast, expression of these p53 target
genes was readily detectable in untreated WT and Set7/9/
MEFs, and their expression was upregulated in response to all
treatments in both WT and Set7/9/ MEFs. Importantly, the
extent of p53 stabilization, its acetylation at K379, as well as
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Set7/9/MEFs andWT controls. This suggests that, in contrast
to what was reported before (Ivanov et al., 2007; Kurash et al.,
2008), Set7/9 is not required to control acetylation of K379 on
p53 and the expression of p53 target genes in MEFs.
Next, we analyzed the cell-cycle profiles of the same MEFs
by BrdU incorporation and PI staining (Figures 2C and 2D).
Whereas p53/ MEFs were mostly unaffected by the treat-
ments, as indicated by their continued BrdU incorporation, WT
and Set7/9/ cells responded to all p53 activating agents by
efficiently stalling DNA synthesis. Moreover, upon extended
exposure to Adriamycin over 24, 48, and 72 hr, WT and
Set7/9/ MEFs induced their respective growth arrests with
equivalent efficiencies (Figure S3). These findings were in stark
contrast to those of Kurash et al. (2008), who reported that
Set7/9/ but not WT MEFs continued to replicate in the pre-
sence of Adriamycin. Furthermore, Kurash et al. (2008) also
reported that Adriamycin-treated Set7/9/ cells displayed a
normal cell-cycle profile with the majority of cells residing in
G1, a finding that was interpreted as a result of diminished p53
activity. In contrast, we observed a characteristic accumulation
of p53/ cells in late S and G2/M phases after Adriamycin treat-
ment, a result that has previously been attributed to pleiotropic
activities of Adriamycin, triggering both p53-dependent G1
arrest and p53-independent G2 arrest (Attardi et al., 2004).
Indeed, p53/ MEFs also responded to sustained exposure to
Adriamycin beyond 24 hr by markedly reducing their growth
rate, likely due to extensive DNA damage caused by the interca-
lating action of Adriamycin resulting in the inability of these cells
to continue replication (Figure S3). Taken together, our results
indicate that Set7/9 is dispensable for p53-dependent transcrip-
tion and for the G1/S phase arrest induced by DNA damage or
culture-associated stress in MEFs.
To investigate whether cell-type-specific defects in the p53
pathway may be present in Set7/9/ animals, we expanded
our analysis to thymic progenitors. These cells are characterized
by high proliferation rates and are very sensitive to apoptotic
stimuli, making them an ideal model to study p53-mediated
cell death (Lowe et al., 1993). We harvested thymocytes from
WT and Set7/9/ mice, subjected them to increasing dosages
of ionizing radiation and quantified apoptosis within these
samples by AnnexinV staining (Figure 2E). Regardless of the
radiation dosage, we detected no significant difference in the
rate with which Set7/9/ and WT thymocytes entered apo-
ptosis. Additionally, we observed no difference in the expression
of p53 target genes p21, Mdm2, and Bax by quantitative real-
time PCR in these cells (Figure 2F). Thus, Set7/9 is not required
for p53-dependent apoptosis in thymic progenitors.
Set7/9–/– MEFs Are Fully Competent to Initiate
Oncogene-Induced Senescence and Apoptosis
and Are Not Predisposed to Transformation
Failsafe mechanisms that sense and counteract uncontrolled
growth signals caused by viral or cellular oncogenes often act
through the p19ARF-mediated inhibition of Mdm2 and concurrent
stabilization of p53. This eventually results in cell-cycle arrest,
also known as premature senescence (Serrano et al., 1997), or
in apoptosis (de Stanchina et al., 1998). To assess the integrityMoof tumor-suppressive responses in cells lacking Set7/9, early-
passage WT, Set7/9/, and p53/ MEFs were infected with
H-RasV12- or E1A-expressing retroviruses and subsequently
assessed for the formation of colonies initiated by immortalized
clones. Unlike p53/ MEFs, which yielded a dramatically
increased number of colonies under all conditions, Set7/9/
MEFs were indistinguishable from WT controls in both colony
numbers and size (Figures 3A and 3B). To determine if
H-RasV12- or E1A-expressing MEFs grow in an anchorage-
independent fashion and if they lost contact inhibition, two
typical hallmarks of cellular transformation, we grew infected
MEFs in soft agar-based culture medium or in high-density
cultures. As expected, p53/MEFs gave rise to readily detect-
able multicellular colonies in soft agar medium when expressing
H-RasV12 or E1A. In contrast, H-RasV12- or E1A-expressingWT
controls and Set7/9/ MEFs yielded no detectable colonies
after 14 days of culture (Figure 3C). Similarly, and unlike what
was reported in Kurash et al. (2008), when grown in high-density
cultures for 21 days, H-RasV12-infected p53/ MEFs formed
foci indicative of cellular transformation, while WT and Set7/9/
cells remained quiescent and in monolayers (Figure S4).
MEFs transformed by combined E1A and H-RasV12 ex-
pression acquire the ability to form tumors when injected sub-
cutaneously in immunocompromised mice (Jimenez et al.,
2000). The growth of these tumors is strongly limited by p53,
thus offering an additional readout for p53 activity. We double-
infected WT, Set7/9/, and p53/ MEFs with E1A and
H-RasV12 and injected them subcutaneously into NOD/SCID
mice. After 14 days, the resulting tumors were harvested and
weighed. As expected, transformed p53/ MEFs gave rise to
very large tumors while those derived from WT and Set7/9/
MEFs were at least one order of magnitude smaller in size. In
addition, we found that WT and Set7/9/ tumors displayed no
significant weight difference (Figure 3D). Together, these results
indicate that loss of Set7/9 is not sufficient to bypass oncogene-
induced senescence and does not attenuate apoptosis in
response to E1A expression in MEFs.
Set7/9 Loss Does Not Accelerate Lymphomagenesis
in Em-Myc Mice
Like E1A, ectopic expression of Myc induces apoptosis through
activation of p19ARF and p53 (Zindy et al., 1998). The transloca-
tion of the c-myc gene under the control of an immunoglobulin
heavy chain (IgH) enhancer is a recurring lesion in the etiology
of Burkitt’s lymphoma. Transgenic mice expressing Myc under
the control of the IgH enhancer (Em-Myc) develop B cell
lymphomas at a mean age of 6 months and thus represent
a sensitizedmodel to study synergistic genetic events underlying
lymphomagenesis (Adams et al., 1985; Hanahan et al., 2007). It is
well established that spontaneous mutations in the p19ARF-
Mdm2-p53 axis occur in lymphomas that arise in these mice
(Eischen et al., 1999), emphasizing a crucial role for p53 in safe-
guarding against hyperproliferative stimuli in this model. Impor-
tantly, targeted mutations in the proapoptotic p53-dependent
effector genes Bax (Eischen et al., 2001), Puma (Garrison et al.,
2008; Hemann et al., 2004), andBim (Egle et al., 2004) also coop-
erate with the Em-Myc transgene and result in markedly accel-
















































































































































































































































































































































Figure 2. Culture-Induced Senescence, DNA Damage-Induced Cell-Cycle Arrest, and Apoptosis Are Unaffected in Set7/9–/– MEFs
and Thymocytes
(A) Two independent MEF preparations for WT, Set7/9/, and p53/ genotypes were cultured according to the 3T3 protocol. Cells from duplicate plates were
counted at each passage, and mean cumulative cell numbers were plotted. Set7/9/ MEFs efficiently enter replicative crisis.
(B) Early-passage MEFs were treated with p53-activating agents; whole-cell lysates were prepared 18 hr later and subjected to western analysis. Under all
conditions tested, the extent of p53K379 acetylation and the expression of Mdm2, p21, or Puma were comparable in Set7/9/ and WT MEFs.
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Myc-driven lymphomagenesis was accelerated in Set7/9/
mice. We bred the p53 null, Set7/9 null, and floxed alleles to
Em-Myc+ mice and transferred Em-Myc+; Set7/9fl/+, Em-Myc+;
Set7/9/, or Em-Myc+; p53+/ fetal liver cells into lethally irradi-
ated C57/B6 CD45.1+ recipients (Figure 3E). We monitored
these mice for enlarged lymph nodes and/or other indications
of B cell lymphoma onset over a time of 6 months. Consistent
with a previous report (Schmitt et al., 2002), all mice in the Em-
Myc+; p53+/ cohort developed lymphomas at a greatly acceler-
ated pace. In contrast, Em-Myc+; Set7/9/ recipients exhibited
no shortened disease latency (Figure 3E) in comparison to Em-
Myc+; Set7/9fl/+ controls, indicating that Set7/9 has no discern-
ible role in regulating p53 activity during lymphomagenesis.
DISCUSSION
Overall, the results we obtained investigating p53 function in
our Set7/9/ mouse strain are not reconcilable with previous
reports, despite the use of very similar assays.
In several crucial points, our results are at odds with those of
Kurash et al. (2008), as well as aspects of the reports by Chuikov
et al. (2004) and Ivanov et al. (2007), thus challenging the notion
that p53 function depends on Set7/9-mediated lysine meth-
ylation in its regulatory C terminus. In summary, we find that (1)
the methylation of murine p53K369 cannot be detected using
an antiserum raised against human p53K372me, (2) the induc-
tion of p53 target genes in response to DNA damage and onco-
genic stress is unaltered in Set7/9/ cells, and accordingly, (3)
no impairment in p53-dependent apoptosis and cell-cycle arrest
is observed in the absence of Set7/9. Importantly, this is in
agreement with the data obtained independently by Testa and
coworkers (Campaner et al., 2011). Hence, while our data do
not formally exclude that p53 may be a Set7/9 substrate in vivo,
they strongly suggest that the proposed role of Set7/9 in p53
regulation requires considerable re-evaluation. Our data also
highlight the requirement to confirm mechanisms of p53 regula-
tion hypothesized based on in vitro studies of transformed cell
lines in primary cells in vivo (Johnson and Attardi, 2006; Toledo
and Wahl, 2006).
Further, our results are consistent with a number of studies
that have addressed the roles of posttranslational lysine modifi-
cations on p53. For example, mutational conversion of all seven
lysines in the C terminus of mouse p53, including K369, into argi-
nines entails onlyminor changes in tumor-suppressive p53 activ-
ities in vivo (Feng et al., 2005; Krummel et al., 2005). Moreover, in
human cells, only the combined mutation of eight lysines,
including two lysines in the DNA binding domain, yields a tran-
scriptionally inert form of p53 (Tang et al., 2008). This result, while(C) The cell-cycle status of the same MEF populations was analyzed by BrdU in
stages are indicated. WT and Set7/9/MEFs respond to all treatments by withdra
in late S and G2 phase in response to Adriamycin.
(D) Cell-cycle analysis summary. G1/S ratios were calculated from three replicat
(E) Quantification of apoptosis in irradiated thymocytes. Thymocytes were prep
radiation dosages. Six hours later, the relative viability was determined by Annex
(F) Quantitative RT-PCR analysis of p53 target genes in irradiated thymocytes. W
indicated dosages. Two hours later, thymocytes were harvested for RT-PCR. We
also corresponding Figures S3 and S4.)
Monot discounting the overall importance of lysine modifications,
strongly suggests that they play highly redundant and/or exqui-
sitely tissue-specific roles. This is in line with the notion that the
activity of p53, because of its fundamental role in tumor sup-
pression, is regulated by a multitude of functionally redundant
mechanisms.
Since cancer formation is a multistep process in which
neoplastic cells progressively acquire genetic or epigenetic
alteration (Hanahan and Weinberg, 2000), Set7/9 might become
a critical lesion in cells that have become deficient in other p53-
regulating pathways. However, our results indicate that loss of
Set7/9 by itself is inconsequential for canonical p53 functions
in vivo.
EXPERIMENTAL PROCEDURES
Generation of Set7/9 Conditional Knockout Mice
Conditional targeting of the Set7/9 genewas done in R1 ESCs and is described
in more detail in Figure S1.
MEF Derivation and Culture
MEFs were prepared from 13.5 dpc embryos according to standard proce-
dures and frozen within 2 days of culture in DMEM, 10% FBS, nonessential
amino acids, l-glutamine, Pen/Strep, and 100 mM b-mercaptoethanol. Thawed
MEF preps were designated as passage 1 and were used until passage 4
maximum.
3T3 Assay
MEFs were plated in duplicate at 3 3 105 cells per 6 cm dish. Every third day,
cells were trypsinized, counted, and replated at original densities over 15
passages.
Thymocyte Apoptosis
Thymocytes were g-irradiated in a 64Co source at 0.5, 1, and 2 Gy. After
overnight culture, viability was determined by AnnexinV-APC and 7AAD
staining on a FACScalibur. For RT-PCR, thymi from sex-matched WT and
Set7/9/ littermates were harvested 2 hr after whole-body irradiation.
RT-PCR
RNA was prepared using RNeasy Mini Kit (QIAGEN) according to the
manufacturer’s instructions. cDNA was generated using the Invitrogen
Superscript III RT protocol. Real-time PCR was done using a Roche
Lightcycler 480 and gene-specific Taqman reagents (Applied Biosystems,
p21: Mm00432448_m1, Mdm2: Mm00487656_m1, Bax: Mm00432050_m1,
GAPDH Hs02758991_g1).
Western Analysis, Immunoprecipitation, and Antibodies
Whole-cell lysates were done in IP buffer (50 mM Tris [pH 7.5], 150 NaCl, 1 mM
EDTA, 1% NP40, Roche Complete protease inhibitors) and processed in
standard western analysis. Antibodies were: a-Set9 (Upstate), a-SET7/9
(Cell Signaling clone C24B1), a-p53 (CM-5, Novocastra), a-p53 (PAb 240,
BD), a-human p53K372me1 (Abcam #16033), a-acetyl-p53K379 (Cell Sig-
naling #2570), a-H3K4me (Abcam), a-p21 (C-19, Santa Cruz), a-p21 (Ab-6,corporation and PI staining. The percentages of cells in the G1, S, and G2/M
wing from the cell cycle. p53/MEFs are characterized by an increased arrest
e experiments as illustrated in (C). Error bars represent standard deviations.
ared from four individual mice of each genotype and exposed to increasing
inV staining and 7AAD exclusion. Error bars represent standard deviations.
T and Set7/9/ mice (n = 4) were exposed to whole-body irradiation at the
detected no impaired induction of p21,Mdm2, and Bax in Set7/9/ cells. (See





Figure 3. Set7/9–/– Cells Respond Normally to Hyperproliferative Stimuli and Are Not Predisposed to Transformation
(A) Passage 2 MEFs of the indicated genotypes were infected with control, H-RasV12, or E1A retroviruses. After Puro selection, 1000 cells were plated on 10 cm
dishes.Colonies scoredbycrystal violet stainingafter 18days revealedacomparablepropensityofWTandSet7/9/MEFs tobe transformedby theseoncogenes.
(B) Summary of transformation assays. Average number of colonies per 1000 cells calculated from ten repeats covering four WT, four Set7/9/, and two p53/
MEF preparations. Error bars represent standard deviations.
(C) Unlike p53/MEFs, Set7/9/MEFs do not acquire anchorage-independent growth when transduced with H-RasV12 or E1A retroviruses. Scale bar is 1mm.
(D) Tumorigenicity of E1A/H-RasV12-infectedMEFs.WT,Set7/9/, and p53/MEFswere doubly infectedwith E1A andH-RasV12, selected by hygro and puro,
and injected subcutaneously into NOD/SCID mice. The weight of tumors harvested after 14 days was comparable between WT and Set7/9/ cells. n = 10
for WT and Set7/9/, n = 5 for p53/, error bars represent standard deviations.
(E) No acceleration inMyc-mediated lymphomagenesis in the absence of Set7/9. Em-Myc+ fetal liver cells (day 14.5) of the indicated genotypeswere transplanted
into irradiated recipient mice by tail vein injection. The time until lymphoma onset, indicated by enlarged lymph nodes, is plotted.
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a-Puma (Cell Signaling #4976).
Retroviral Gene Transfer
The retroviral transfer vectors pWZL E1A hygro and pBabe RasV12 puro were
obtained from Scott Lowe (CSHL). Virus production was performed in Phoenix
E cells according to standard procedures. Infected MEFs were selected with
hygromycin (200 mg/ml) or puromycin (2 mg/ml) for 48 hr.
Tumor Graft Assays
43 106 pWZL E1A hygro and pBabe RasV12 puro double-infectedMEFs were
injected subcutaneously into NOD/SCID mice. The resulting tumors were
dissected and weighed after 14 days.
Cell-Cycle Analysis
Early-passage MEFs were treated with p53-activating agents overnight and
pulsed with 10 mM BrdU for 60 min. BrdU/PI detection was performed using
FITC-conjugated anti-BrdU (BD Cat. No. 556028) according to the manufac-
turer’s instructions.
Em-Myc+ Lymphoma Onset Assay
Em-Myc+ (JAX #02728) 3 Set7fl/+, Set7/, or p53+/ fetal livers were trans-
planted into lethally irradiated recipients. The recipients were euthanized at
lymphoma onset, characterized by enlarged lymph nodes and spleens.
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